The association between the expression of Survivin mRNA and ovarian cancer: a meta-analysis_Chinese Journal of Evidence-Based Medicine

Authors：

XU Yingyi , ZHANG Yaya , LIN Zhicai ,  CHEN Yuqiang

Department of Oncology, Chenggong Hospital Affiliated to Xiamen University, No.174 Hospital of PLA, Xiamen, 361003, P.R.China;

Corresponding?author：

CHEN Yuqiang, Email: chenyq707@163.com

Keywords：

Survivin; Ovarian neoplasms; Meta-analysis; Systematic review; Case-control study

DOI：

10.7507/1672-2531.201611081

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To systematically review the relationship between the expression of Survivin mRNA and ovarian cancer. Methods PubMed, The Cochrane Library (Issue 11, 2016), CBM, CNKI, VIP and WanFang Data databases were searched to identify case-control studies concerning the association between the expression of Survivin mRNA and ovarian cancer up to November 2016. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies. Then, meta-analysis was performed using RevMan 5.2 software. Results A total of 10 studies were included. The positive of Survivin mRNA in ovarian cancer group was significantly higher than that in control group (OR=24.63, 95% CI 13.44 to 45.15,P<0.000 01). The positive of Survivin in low differentiated group was significantly higher than that in high differentiation group (OR=3.69, 95% CI 2.29 to 5.93,P<0.000 01). The positive of Survivin in clinical stage of Ⅲ-Ⅳ was significantly higher than that in clinical stage of Ⅰ-Ⅱ (OR=4.76, 95% CI 2.99 to 7.57,P<0.000 01), respectively. However, the expression of Survivin mRNA was not associated with lymph node metastasis, ascites and histological type. Conclusion The current evidence indicates that the expression of Survivin mRNA is significantly correlated with ovarian cancer and its clinicopathologic features. Due to the limited quantity and quality of includes studies, the above conclusions are needed to be verified by more high quality studies.

Citation： XU Yingyi, ZHANG Yaya, LIN Zhicai, CHEN Yuqiang. The association between the expression of Survivin mRNA and ovarian cancer: a meta-analysis. Chinese Journal of Evidence-Based Medicine, 2017, 17(3): 320-326. doi: 10.7507/1672-2531.201611081 Copy

1.	?Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin, 2005, 55(2): 74-108.
2.	Basu P, De P, Mandal S, et al. Study of pattern of care of ovarian cancer patients in specialized cancer institute in Kolkata, Eastern India. Indian J Cancer, 2009, 46(1): 28-33.
3.	Modepalli N, Venugopal SB. Clinicopathological study of surface epithelial tumours of the ovary: an isntitutional study. J Clin Diagn Res, 2016, 10(10): EC01-EC04.
4.	李克紅, 張若曦, 張英杰, 等. 凋亡抑制基因 Survivin 在卵巢癌組織中的表達及其臨床意義. 中國實用醫刊, 2012, 39(8): 4-6.
5.	史惠蓉, 蘭莉, 喬玉環, 等. 卵巢癌組織中 Survivin 和 PCNA 的表達. 鄭州大學學報(醫學版), 2004, 39(4): 552-554.
6.	宋和存, 向征, 李慧. Survivin Ki67 在卵巢原發癌與轉移癌中的表達及其臨床意義. 中國實用婦科與產科雜志, 2006, 22(3): 201-203.
7.	王言奎, 楊錦芝, 羅兵, 等. 上皮性卵巢癌中 Survivin 的表達及意義. 中國婦產科臨床雜志, 2003, 4(5): 368-372.
8.	楊錦芝, 趙冬梅. 凋亡抑制基因 Survivin 在上皮性卵巢癌中的表達及其意義. 濱州醫學院學報, 2003, 26(4): 243-244.
9.	Li GZ, Pei SL, Hong LM, et al. Survivin expression in ovarian cancer. Exp Oncol, 2007, 29(2): 121-125.
10.	張淑蘭, 趙長清, 林蓓, 等. 凋亡抑制基因 survivin 在卵巢上皮性癌組織中的表達及其與 bcl-2、bax 蛋白表達的關系. 中華婦產科雜志, 2003, 38(4): 203-206.
11.	張樹榮, 楊淑莉, 李荷蓮. 卵巢癌組織中 MDR1、Survivin、TopoⅡβ 的表達及臨床意義. 中國婦幼健康研究, 2006, 17(6): 464-466.
12.	張意茗, 張向寧. XIAP、survivin、LPA 及 CA125 在上皮性卵巢癌中的表達. 山東大學學報(醫學版), 2007, 45(3): 317-321.
13.	趙楊, 張頤, 溫放. 凋亡抑制蛋白和耐藥因子在卵巢癌中的表達及與化療的關系. 解剖科學進展, 2007, 13(2): 111-114, 118.
14.	Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the qualityof nonrandomized studies in meta-analysis. Available at: .
15.	許英藝, 張雅雅, 盧偉鋒, 等. 骨橋蛋白表達與中國人肝癌及臨床病理特征關系的 Meta 分析. 中國循證醫學雜志, 14(12): 1418-1423.
16.	Ambrosini G, Adida C, Sirugo G, et al. Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J Biol Chem, 1998, 273(18): 11177-11182.
17.	Shin S, Sung BJ, Cho YS, et al. An anti-apoptotic protein human a survivin is a direct inhibitor of caspase-3 and -7. Biochemistry, 2001, 40(4): 1117-1123.
18.	Grossman D, McNiff JM, Li F, et al. Expression and targeting of the apoptosis inhibtitor, Survivin, in nonmelanoma skin cancer and gene targeting in a keratinocyte cell line. Lab Invest, 1999, 79(9): 1121-1126.
19.	Grossman D, McNiff JM, Li F, et al. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol, 1999, 113(6): 1076-1081.
20.	Nasu S, Yangihashi A, Izawa A, et al. Survivin mRNA expression in patients with breast cancer. Anticancer Res, 2002, 22(3): 1839-1843.
21.	Smith SD, Wheeler MA, Plescia J, et al. Urine detection of survivin and diagnosis of bladder cancer. JAMA, 2001, 285(3): 324-328.
22.	Ambrosini G, Adjda C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphma. Nat Med, 1997, 3(8): 917-921.
23.	Marx D, Binder C, Meden H, et al. Differential expression of apoptosis associated gene bax and bcl-2 in ovarian cancer. Anticancer Res, 1997, 17(3C): 2233-2240.

1. ?Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin, 2005, 55(2): 74-108.
2. Basu P, De P, Mandal S, et al. Study of pattern of care of ovarian cancer patients in specialized cancer institute in Kolkata, Eastern India. Indian J Cancer, 2009, 46(1): 28-33.
3. Modepalli N, Venugopal SB. Clinicopathological study of surface epithelial tumours of the ovary: an isntitutional study. J Clin Diagn Res, 2016, 10(10): EC01-EC04.
4. 李克紅, 張若曦, 張英杰, 等. 凋亡抑制基因 Survivin 在卵巢癌組織中的表達及其臨床意義. 中國實用醫刊, 2012, 39(8): 4-6.
5. 史惠蓉, 蘭莉, 喬玉環, 等. 卵巢癌組織中 Survivin 和 PCNA 的表達. 鄭州大學學報(醫學版), 2004, 39(4): 552-554.
6. 宋和存, 向征, 李慧. Survivin Ki67 在卵巢原發癌與轉移癌中的表達及其臨床意義. 中國實用婦科與產科雜志, 2006, 22(3): 201-203.
7. 王言奎, 楊錦芝, 羅兵, 等. 上皮性卵巢癌中 Survivin 的表達及意義. 中國婦產科臨床雜志, 2003, 4(5): 368-372.
8. 楊錦芝, 趙冬梅. 凋亡抑制基因 Survivin 在上皮性卵巢癌中的表達及其意義. 濱州醫學院學報, 2003, 26(4): 243-244.
9. Li GZ, Pei SL, Hong LM, et al. Survivin expression in ovarian cancer. Exp Oncol, 2007, 29(2): 121-125.
10. 張淑蘭, 趙長清, 林蓓, 等. 凋亡抑制基因 survivin 在卵巢上皮性癌組織中的表達及其與 bcl-2、bax 蛋白表達的關系. 中華婦產科雜志, 2003, 38(4): 203-206.
11. 張樹榮, 楊淑莉, 李荷蓮. 卵巢癌組織中 MDR1、Survivin、TopoⅡβ 的表達及臨床意義. 中國婦幼健康研究, 2006, 17(6): 464-466.
12. 張意茗, 張向寧. XIAP、survivin、LPA 及 CA125 在上皮性卵巢癌中的表達. 山東大學學報(醫學版), 2007, 45(3): 317-321.
13. 趙楊, 張頤, 溫放. 凋亡抑制蛋白和耐藥因子在卵巢癌中的表達及與化療的關系. 解剖科學進展, 2007, 13(2): 111-114, 118.
14. Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the qualityof nonrandomized studies in meta-analysis. Available at: .
15. 許英藝, 張雅雅, 盧偉鋒, 等. 骨橋蛋白表達與中國人肝癌及臨床病理特征關系的 Meta 分析. 中國循證醫學雜志, 14(12): 1418-1423.
16. Ambrosini G, Adida C, Sirugo G, et al. Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J Biol Chem, 1998, 273(18): 11177-11182.
17. Shin S, Sung BJ, Cho YS, et al. An anti-apoptotic protein human a survivin is a direct inhibitor of caspase-3 and -7. Biochemistry, 2001, 40(4): 1117-1123.
18. Grossman D, McNiff JM, Li F, et al. Expression and targeting of the apoptosis inhibtitor, Survivin, in nonmelanoma skin cancer and gene targeting in a keratinocyte cell line. Lab Invest, 1999, 79(9): 1121-1126.
19. Grossman D, McNiff JM, Li F, et al. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol, 1999, 113(6): 1076-1081.
20. Nasu S, Yangihashi A, Izawa A, et al. Survivin mRNA expression in patients with breast cancer. Anticancer Res, 2002, 22(3): 1839-1843.
21. Smith SD, Wheeler MA, Plescia J, et al. Urine detection of survivin and diagnosis of bladder cancer. JAMA, 2001, 285(3): 324-328.
22. Ambrosini G, Adjda C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphma. Nat Med, 1997, 3(8): 917-921.
23. Marx D, Binder C, Meden H, et al. Differential expression of apoptosis associated gene bax and bcl-2 in ovarian cancer. Anticancer Res, 1997, 17(3C): 2233-2240.

Chinese Journal of Evidence-Based Medicine

The association between the expression of Survivin mRNA and ovarian cancer: a meta-analysis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content